515,025 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by Mirador Capital Partners LP

Mirador Capital Partners LP purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 515,025 shares of the biotechnology company’s stock, valued at approximately $1,118,000.

Other institutional investors also recently bought and sold shares of the company. Osaic Holdings Inc. raised its position in shares of Iovance Biotherapeutics by 106.7% in the 2nd quarter. Osaic Holdings Inc. now owns 88,856 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 45,877 shares during the last quarter. Squarepoint Ops LLC lifted its stake in Iovance Biotherapeutics by 115.2% during the 2nd quarter. Squarepoint Ops LLC now owns 856,569 shares of the biotechnology company’s stock valued at $1,473,000 after acquiring an additional 458,540 shares during the period. Cim Investment Management Inc. lifted its stake in Iovance Biotherapeutics by 100.7% during the 2nd quarter. Cim Investment Management Inc. now owns 61,117 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 30,671 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Iovance Biotherapeutics in the 2nd quarter valued at $75,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Iovance Biotherapeutics by 277.4% in the second quarter. Tower Research Capital LLC TRC now owns 41,723 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 30,668 shares during the period. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Trading Up 4.2%

IOVA stock opened at $2.25 on Wednesday. The firm has a 50-day moving average of $2.24 and a two-hundred day moving average of $2.25. Iovance Biotherapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $8.15. The company has a market cap of $893.18 million, a price-to-earnings ratio of -1.87 and a beta of 0.83.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. Iovance Biotherapeutics had a negative return on equity of 55.24% and a negative net margin of 158.78%.The company had revenue of $67.46 million during the quarter, compared to analysts’ expectations of $76.20 million. As a group, equities analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. HC Wainwright decreased their target price on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Iovance Biotherapeutics in a report on Wednesday, October 8th. Barclays reaffirmed an “overweight” rating on shares of Iovance Biotherapeutics in a report on Wednesday. Finally, Chardan Capital reduced their price target on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Iovance Biotherapeutics has an average rating of “Hold” and a consensus price target of $11.00.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.